Drug tolerance and persistence to EGFR inhibitor treatment are mediated by an ILK-SFK-YAP signaling axis in lung adenocarcinoma.
Saved in:
| Title: | Drug tolerance and persistence to EGFR inhibitor treatment are mediated by an ILK-SFK-YAP signaling axis in lung adenocarcinoma. |
|---|---|
| Authors: | Shi R; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada., Farnsworth DA; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada., Febres-Aldana CA; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Chow JLM; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada., Sheena R; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada., Atwal T; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada., Gomez Marti JL; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Li S; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada., Thomas KN; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada., Lee CM; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada., Awrey SJ; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada., McDonald PC; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada., Somwar R; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Dedhar S; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada.; Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, BC, Canada., Ladanyi M; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Bennewith KL; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada.; Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada., Lockwood WW; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada. wlockwood@bccrc.ca.; Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada. wlockwood@bccrc.ca. |
| Source: | Oncogene [Oncogene] 2025 Aug; Vol. 44 (32), pp. 2831-2849. Date of Electronic Publication: 2025 May 31. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8711562 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5594 (Electronic) Linking ISSN: 09509232 NLM ISO Abbreviation: Oncogene Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
